Access Bio (Korea) Performance
| 950130 Stock | KRW 5,540 170.00 2.98% |
The firm shows a Beta (market volatility) of 0.0889, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Access Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Access Bio is expected to be smaller as well. At this point, Access Bio has a negative expected return of -0.31%. Please make sure to confirm Access Bio's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if Access Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Access Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | -29.5 M |
Access |
Access Bio Relative Risk vs. Return Landscape
If you would invest 677,000 in Access Bio on September 3, 2024 and sell it today you would lose (123,000) from holding Access Bio or give up 18.17% of portfolio value over 90 days. Access Bio is generating negative expected returns and assumes 2.2367% volatility on return distribution over the 90 days horizon. Simply put, 19% of stocks are less volatile than Access, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Access Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Access Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Access Bio, and traders can use it to determine the average amount a Access Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1407
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 950130 |
Estimated Market Risk
| 2.24 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Access Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Access Bio by adding Access Bio to a well-diversified portfolio.
Access Bio Fundamentals Growth
Access Stock prices reflect investors' perceptions of the future prospects and financial health of Access Bio, and Access Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Access Stock performance.
| Return On Equity | 108.02 | |||
| Return On Asset | 0.35 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | 0.55 % | |||
| Current Valuation | 1.03 T | |||
| Shares Outstanding | 26.79 M | |||
| Price To Earning | 149.71 X | |||
| Price To Sales | 1.44 X | |||
| Revenue | 441.37 M | |||
| EBITDA | 69.95 B | |||
| Cash And Equivalents | 167.93 M | |||
| Cash Per Share | 828.78 X | |||
| Total Debt | 10.13 M | |||
| Debt To Equity | 0.13 % | |||
| Book Value Per Share | 2,289 X | |||
| Cash Flow From Operations | 137.9 M | |||
| Total Asset | 372.85 M | |||
| Retained Earnings | 18.8 B | |||
| Current Asset | 45.78 B | |||
| Current Liabilities | 2.1 B | |||
About Access Bio Performance
By analyzing Access Bio's fundamental ratios, stakeholders can gain valuable insights into Access Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Access Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Access Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Access Bio, Inc. researches, develops, and manufactures in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products.Things to note about Access Bio performance evaluation
Checking the ongoing alerts about Access Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Access Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Access Bio generated a negative expected return over the last 90 days | |
| About 25.0% of the company shares are owned by insiders or employees |
- Analyzing Access Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Access Bio's stock is overvalued or undervalued compared to its peers.
- Examining Access Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Access Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Access Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Access Bio's stock. These opinions can provide insight into Access Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Access Stock analysis
When running Access Bio's price analysis, check to measure Access Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Access Bio is operating at the current time. Most of Access Bio's value examination focuses on studying past and present price action to predict the probability of Access Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Access Bio's price. Additionally, you may evaluate how the addition of Access Bio to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |